pharma news today glp-1 obesity drug updates The United States Agonists Weight Loss Drugs Market Size & Outlook, 2030 What is the pipeline for

Clinical studies Compared with the considerable amount of pre-clinical and mechanistic research reported above, we identified few clinical studies of GLP-1RAs for substance-use disorders (Table 2): three for alcohol 111,112,113 , one for cannabis 114 , two for cocaine 115,116 and two for nicotine 117,118 , while no article about opiates or amphetamines was retrieved

Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects

In bacteria, copper not only damages the cell membrane, but also the DNA, due to the intrusion of copper ions and resulting oxidative stress (Grass et al., 2011

10.1016/j.biopha.2022.113207 275 XavierJ.AnuM.FathimaA.RavichandiranV.KumarN